PHENOTYPIC PERSONALIZED MEDICINE (PPM)™
The advent of the Phenotypic Personalized Medicine (PPM)™ platform has completely changed the way that patient therapy is designed. From more powerful medicines to truly tailored treatment regimens, KYAN has made optimizing care a reality.
Finding the needle in a haystack.
Or a galaxy. Identifying truly optimal drug-dose ratios in drug development or patient therapy has been virtually impossible. Until now. KYAN's proprietary technology platforms have revolutionized that way that we approach both challenges. Our approach definitely pinpoints the best parameters for drug development and individualized patient therapy.
Agnostic to disease mechanism.
By creating phenotypic maps based on the patient's actual clinical data, KYAN is not limited by un-actionable genomic or proteomic information.
Agnostic to disease model.
KYAN does not utilize preclinical data to drive clinical drug-dose ratios. We re-optimize and de-risk at each stage of development.
With KYAN, It's Personal.
In nearly every KYAN drug development and personalized treatment program, we have also discovered that conventional clinical drug combinations and/or dosing are non-optimal. KYAN challenges convention to develop the best medicines possible and ensures that patient therapy is truly optimized.
KYAN has developed proprietary novel drug combinations in months instead of years. We have also made unprecedented advances in tailored treatment.
KYAN's technology portfolio is published in several of the most prestigious peer-reviewed publications in the world. Please refer to the list below to learn about our most recent breakthroughs:
A. Zarrinpar...C.M. Ho, and D. Ho, SCIENCE TRANSLATIONAL MEDICINE, 2016.
D. Ho, K.C.-H. Wang, and E.K.-H. Chow, SCIENCE ADVANCES, 2015.
E.K.-H. Chow, and D. Ho, SCIENCE TRANSLATIONAL MEDICINE, 2013.
H. Wang, C.-M. Ho, and D. Ho, et al. ACS NANO, 2015.
H. Tsutsui, C.-M. Ho, et al., NATURE COMMUNICATIONS, 2011.
P.K. Wong, C.-M. Ho, et al., PNAS, 2007.